Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Chemoradiotherapy After Surgery Compared With Surgery Alone For Adenocarcinoma Of The Stomach Or Gastroesophageal Junction.

J. Macdonald, S. Smalley, J. Benedetti, S. Hundahl, N. Estes, G. Stemmermann, D. Haller, J. Ajani, L. Gunderson, J. Jessup, J. Martenson
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction. METHODS A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart. RESULTS The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P<0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent. CONCLUSIONS Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.
This paper references
CLINICAL ONCOLOGY
J. Horton (1978)
Early evaluation of 5FU plus leucovorin (LV) as a radiation enhancer for gastrointestinal carcinoma
JA Malliard (1991)
10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S
The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy
S. Hundahl (2000)
10.1016/S0959-8049(01)80998-9
Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial
J. Fielding (2001)
10.1200/JCO.1993.11.8.1441
Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.
J. Hermans (1993)
10.1002/BJS.1800750206
Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma
D. Dent (1988)
10.1016/0360-3016(82)90377-7
Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.
L. Gunderson (1982)
Regression Models and Life-Tables
D.
[Extended lymph-node dissection for gastric cancer].
M. Huguier (1999)
10.1200/JCO.1989.7.10.1407
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
M. A. Poon (1989)
10.1097/00000658-199321850-00002
Cancer of the stomach. A patient care study by the American College of Surgeons.
H. Wanebo (1993)
10.1016/0360-3016(90)90344-J
Patterns of failure following curative resection of gastric carcinoma.
J. Landry (1990)
10.1002/1097-0142(19820501)49:9<1771::AID-CNCR2820490907>3.0.CO;2-M
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma
P. Schein (1982)
10.1016/S0140-6736(69)92326-5
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
C. Moertel (1969)
10.1097/00000658-195107000-00002
A CRITICAL EVALUATION OF SUBTOTAL GASTRECTOMY FOR THE CURE OF CANCER OF THE STOMACH
G. Mcneer (1951)
Local recurrence following subtotal resection for gastric carcinoma.
F. Thomson (1952)
10.1016/S0959-8049(99)00076-3
Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.
C. Earle (1999)
10.1200/JCO.1997.15.5.2030
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
J. Tepper (1997)
10.1016/S0360-3016(98)00280-6
Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients.
Z. Zhang (1998)
10.1016/S1055-3207(18)30409-5
Gastric cancer nodal metastases: biologic significance and therapeutic considerations.
S. Hundahl (1996)
10.1016/S0140-6736(75)90249-4
ORAL HYPOGLYCÆMICS IN DIABETES MELLITUS
H. Keen (1975)
10.7326/0003-4819-99-3-429_1
Manual for Staging of Cancer
O. Beahrs (1992)
Intra-operative radiotherapy for carcinoma of the stomach.
M. Takahashi (1986)
Surgical treatment of gastric cancer: anatomical borders and dissection of lymph nodes.
C. V. D. van de Velde (1998)
10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M
Adenocarcinoma of the stomach: Review of 1,497 cases
J. Dupont (1978)



This paper is referenced by
10.21037/jgo.2018.03.05
Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma.
R. Zhu (2018)
10.1016/S0022-5223(03)00941-3
Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction.
T. Lerut (2003)
10.1111/ans.15011
Predictors of survival outcome following radical gastrectomy for gastric cancer
Su-Ann Lui (2019)
10.1371/journal.pone.0070191
Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer
Q. Wang (2013)
10.1097/SLA.0b013e318262a591
Proposal for a Multifactorial Prognostic Score That Accurately Classifies 3 Groups of Gastric Carcinoma Patients With Different Outcomes After Neoadjuvant Chemotherapy and Surgery
K. Becker (2012)
10.1038/bjc.2016.252
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer
P. Martín-Romano (2016)
10.1586/14737140.2016.1121110
Targeting HER 2 and angiogenesis in gastric cancer
G. Jomrich (2016)
10.3349/ymj.2015.56.5.1177
Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine
Y. Y. Choi (2015)
10.1186/s12876-016-0422-7
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis
Q. He (2016)
10.24875/RIC.18002622
BURSECTOMY IN GASTRIC CANCER SURGERY: A META-ANALYSIS.
Y. Li (2019)
10.1007/s10269-007-0654-9
Carcinome adéno-squameux de l’estomac. À propos de deux cas
M. Bel Haj Salah (2007)
10.21037/TGH.2020.03.01
Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma
E. Ludmir (2020)
10.5230/jgc.2012.12.2.55
Comparisons of Gastric Cancer Treatments: East vs. West
K. Bickenbach (2012)
10.1002/bjs.5729
Hospital volume does not influence long‐term survival of patients undergoing surgery for oesophageal or gastric cancer
A. Thompson (2007)
10.1002/cncr.31160
Conditional survival of patients with gastric cancer who undergo curative resection: A multi‐institutional analysis in China
P. Wang (2018)
10.1002/bjs.5240
Extranodal metastasis is an indicator of poor prognosis in patients with gastric carcinoma
T. Etoh (2006)
10.1002/jso.25755
Positive node‐ratio in curative‐intent treatment for gastric cancer is a strong independent prognostic factor for 5‐year overall survival
D. Wohnrath (2019)
10.2147/CMAR.S232930
The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma
T. Song (2020)
10.1097/SLA.0b013e31824857e2
Comparison of a Lymph Node Ratio–Based Staging System With the 7th AJCC System for Gastric Cancer: Analysis of 18,043 Patients From the SEER Database
J. Wang (2012)
10.1002/bjs.6371
Author's reply: Gastric cancer in Europe (Br J Surg 2008; 95: 406–408)
W. Allum (2008)
A five split-field three dimensional conformal technique versus an anterior-posterior on in postoperative radiotherapy for gastric carcinoma: a multicenter comparative study using quality of life measurements as well as clinical and dosimetric parameters.
A. Zygogianni (2018)
10.1097/01.COC.0000074148.37768.3E
COX-2 Inhibitors as Radiation Sensitizers for Upper GI Tract Cancers: Esophagus, Stomach, and Pancreas
T. Rich (2003)
10.1097/MD.0000000000023795
Recurrence pattern and its predictors for advanced gastric cancer after total gastrectomy
Xu-guang Jiao (2020)
10.5580/2258
A Case to Remember: Enlarged Gastric Folds —A Management Dilemma
B. Qazi (2009)
10.1155/2012/368428
Complete Response of Liver Metastasis of Gastric Cancer Treated by S-1 Chemoradiotherapy: A Case Report
Tomonori Miyazawa (2012)
10.3892/ol.2020.12160
Expression and clinical correlation of Survivin and PTEN in gastric cancer patients
Aikeremu Yusufu (2020)
10.12865/CHSJ.42.03.04
Clinical, Histological and Prognosis Correlations in Diagnosis and Treatment of Gastric Cancer
A. Crişan (2016)
10.1097/PPO.0b013e318178d23a
Outcomes of Adjuvant Chemoradiotherapy After a Radical Gastrectomy and a D2 Node Dissection for Gastric Adenocarcinoma
C. Leong (2008)
10.5230/jgc.2016.16.4.271
The Rare and Challenging Presentation of Gastric Cancer during Pregnancy: A Report of Three Cases
Sergio Pacheco (2016)
10.1080/02841860902740915
Follow up your unexpected clinical observations!
Olav Dahl (2009)
Neoadjuvant treatment for gastric cancer in the West: a critical review
Wilson Luiz da Costa (2014)
10.1517/14656566.6.16.2805
Gastric and gastro-oesophageal cancer therapy
P. Das (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar